Comparing effects of biologic agents in treating patients with rheumatoid arthritis: A multiple treatment comparison regression analysis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Tvete, Ingunn Fride ^a   Natvig, Bent ^b   Gåsemyr, Jørund ^b   Meland, Nils ^c   Røine, Marianne ^c   Klemp, Marianne ^b,d  

^a NORWEGIAN COMPUTING CENTER   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Smerud Medical Research International AS   (Norway)

^d NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ARTICLE; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; META ANALYSIS; PROBABILITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; HUMANS; PROBABILITY; REGRESSION ANALYSIS;

EID: 84944811040     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137258     Document Type: Article

References (70)

1. Lard LR, Visser H, Spreyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446-51. PMID: 11690569
2. Olsen NJ, Stein M. New drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-79.
3. J Rheumatol Suppl. 2002 Nov; 66:3-8. PMID: 15152062
4. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol Suppl. 2002 Nov; 66: 3-8. PMID: 12435162
5. http://www.nhs.uk/Conditions/Rheumatoid-arthritis/Pages/Treatment.aspx
6. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Research May 2012; Vol. 64, No. 5, 625-639.
7. Thorlund K, Druyts E, Aviña-Zubieta JA, Wu P, Mills EJ. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann Rheum Dis 2013; 72:1524-1535 doi: 10.1136/annrheumdis-2012-201574 PMID: 23087184
8. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of Infliximab Combined with Low Dose Methotrexate in Japanese Patients with Rheumatoid Arthritis. J Rheumatol 2006; 33; 37-44. PMID: 16395748
9. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67:1516-1523. doi: 10.1136/ard.2008.092932 PMID: 18625622
10. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et-al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58:2968-80. doi: 10.1002/art.23940 PMID: 18821691
11. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. ARTHRITIS & RHEUMATISM Vol. 54, No. 9, September 2006, 2817-2829.
12. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97. doi: 10.1016/S0140-6736(08)60453-5 PMID: 18358926
13. Chen DY, Chou SJ, Tsu-Yi Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis. J Formos Med Assoc 2009, Vol 108, No 4.
14. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of Rheumatoid Arthritis With Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, in Combination With Methotrexate. ARTHRITIS & RHEUMATISM. Vol. 46, No. 3, March 2002, 614-624.
15. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. for the 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63:1062-1068. PMID: 15082469
16. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N Engl J Med 2004; 350:2572-81. PMID: 15201414
17. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. for the DANCER Study Group. The Efficacy and Safety of Rituximab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Treatment. ARTHRITIS & RHEUMATISM Vol. 54, No. 5, May 2006b, 1390-1400.
18. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis. ARTHRITIS & RHEUMATISM Vol. 60, No. 8, August 2009, 2272-2283.
19. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX in adequate responders (SERENE)). Ann Rheum Dis 2010; 69:1629-1635. doi: 10.1136/ard.2009.119933 PMID: 20488885
20. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous diseasemodifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68:805-811. doi: 10.1136/ard.2008.099291 PMID: 19015206
21. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. Ann Intern Med. 2006; 144:865-876. PMID: 16785475
22. Lipsky PE, van der Heijde D, St. Clair W, Furst DE, Breedveld FC, Kalden JRK, et al. for the Anti-Tumor Necrosis Factor T Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-1602. PMID: 11096166
23. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-39. PMID: 10622295
24. Miyasaka N: The CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol (2008) 18: 252-262. doi: 10.1007/s10165-008-0045-0 PMID: 18330677
25. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial. Ann Intern Med. 1999; 130: 478-486. PMID: 10075615
26. van de Putte LBA, Rau R, Breedveld FC, Kalden JK, Malaise MG, van Riel PLCM, et al. Efficacy and safety of the fully human anti-tumour necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62:12, 1168-1177.
27. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63:5, 508-516.
28. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal. ARTHRITIS & RHEUMATISM Vol. 52, No. 1, January 2005, 27-35.
29. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008 Aug; 67(8): 1096-103. PMID: 18055472
30. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50:1761-9. PMID: 15188351
31. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-1167. PMID: 17485422
32. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68:1580-4. doi: 10.1136/ard.2008.092866 PMID: 19019888
33. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804. doi: 10.1136/ard.2008.101659 PMID: 19015207
34. St. Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. for the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis & Rheumatism, 2004, 50: 3432-3443.
35. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. Atrial of etaner-cept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28; 340(4): 253-9. PMID: 9920948
36. Weinblatt ME, Keystone EC, Furst DE, Moredland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45. PMID: 12528101
37. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. for the START Study Group. The Safety of Infliximab, Combined With Background Treatments, Among Patients With Rheumatoid Arthritis and Various Comorbidities. ARTHRITIS & RHEUMATISM Vol. 54, No. 4, April 2006, 1075-1086.
38. Zhang FC, Hou Y, Huang F, Wu DH, Bao CD, Ni LQ, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 2006, 9(2): 127-130
39. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol December 2003 30(12): 2563-2571.
40. Genovese M, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, et al: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114-23. PMID: 16162882
41. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumabin patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo controlled, dose-ranging study. Arthritis Rheum 2008a; 58: 964-75.
42. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, Clinical, and Functional Outcomes of Treatment With Adalimumab (a Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy. ARTHRITIS & RHEUMATISM Vol. 50, No. 5, May 2004, 1400-1411.
43. Keystone E, van der Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 2008; 58: 3319-29. doi: 10.1002/art.23964 PMID: 18975346
44. Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Bin Yoo B, et al. A randomized, double-blind, placebocontrolled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with Methotrexate. APLAR Journal of Rheumatology 2007; 10: 9-16.
45. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. for TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28; 363 (9410): 675-81. PMID: 15001324
46. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of Rheumatoid Arthritis With the Selective Costimulation Modulator Abatacept. ARTHRITIS & RHEUMATISM Vol. 52, No. 8, August 2005, 2263-2271.
47. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789-796. doi: 10.1136/ard.2008.099010 PMID: 19066176
48. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. for the REFLEX Trial Group. Rituximab for Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Therapy: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating Primary Efficacy and Safety at Twenty-Four Weeks. ARTHRITIS & RHEUMATISM; Vol. 54, No. 9, September 2006, 2793-2806.
49. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008b; 372: 375-82.
50. Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013; 72: 844-850. doi: 10.1136/annrheumdis-2012-201612 PMID: 22739990
51. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72: 64-71. doi: 10.1136/annrheumdis-2011-201247 PMID: 22562973
52. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39-46. doi: 10.1136/ard.2010.137703 PMID: 20937671
53. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-621. doi: 10.1002/art.30158 PMID: 21360490
54. Choy E, McKenna F, Vencovsky J, Valente R, Goel N, VanLunen B, Davies O, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 2012; 51:1226-1234. doi: 10.1093/rheumatology/ker519 PMID: 22344576
55. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012; 71: 817-24. doi: 10.1136/ard.2011.200317 PMID: 22121129
56. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a New Human Anti-Tumor Necrosis Factor-Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis: Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study. ARTHRITIS & RHEUMATISM Vol. 62, No. 4, April 2010, 917-928.
57. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96. doi: 10.1136/ard.2008.105197 PMID: 19297346
58. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012; 71:198-205. doi: 10.1136/ard.2010.148700 PMID: 21949007
59. Breedveld FC1, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 Jan; 54(1): 26-37.59.59. PMID: 16385520
60. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68:1870-7. doi: 10.1136/ard.2008.101121 PMID: 19124524
61. Weinblatt ME, Schiff M, Valente R, Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan; 65(1): 28-38. doi: 10.1002/art.37711 PMID: 23169319
62. http://www.rheumatology.org/
63. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A review and bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol 2011; 31, 6, 698-704.
64. Thomas A. BUGS: a statistical modelling package RTA/BCS Modular Languages Newsletter. 1994; vol 2, 36-38.
65. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
66. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statist. Med. 2007; 26:1237-1254.
67. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview CMAJ. 2009 Nov 24; 181(11):787-96. doi: 10.1503/cmaj.091391 PMID: 19884297
68. Divine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 2011; Vol 31, No 1.
69. Turkstra E, Ng SK, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Current Medical Research & Opinion 2011; Vol. 27, No. 10, 1885-1897.
70. Mandema JW, Salinger DH, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther. 2011 Dec; 90(6):828-35. doi: 10.1038/clpt.2011.256 PMID: 22048227